Evaluation of a New Surgical Technique for Macular Hole Which Was Not Closed After a Previous Surgery

NCT ID: NCT02946372

Last Updated: 2025-11-20

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-30
• Study Completion Date: 2017-06-30

Brief Summary

Macular hole is an infrequent retinal pathology (2 to 4/1000) which most often affects people aged over 60, and twice common in women than men.

The vast majority of cases are idiopathic. Without treatment, the macular hole evolves through a series of stages until the extension of the diameter (up to 500 microns and higher values). With a fully developed macular hole, patients complain of metamorphopsia and decreased visual acuity.

This pathology has clearly benefited from advances in microsurgery and better understanding of its pathophysiology. Macular hole treatment has evolved to include small-gauge pars plana vitrectomy with or without internal limiting membrane (ILM) peeling and placement of intraocular gas tamponade.

The postoperative closure rate is close to 80%, but strongly depends on the initial characteristics of the hole, its diameter remaining the main prognostic factor. Thus for macular holes <400 microns, the closure rate is close to 92% dropping to 56% for macular holes above 400 microns. In case of surgical failure, one or more reoperations can be proposed, but with a lower closure rate.

The quest for a surgical technique presenting a greater success rate is a common goal to all retinologists.

Here the investigators propose a new surgical technique, derived from the FLAP method, and consisting of an inner limiting membrane transposition.

The objective of this study is to evaluate the feasibility of a new surgical technique for the treatment of macular holes already operated but without macular hole closure, allowing these patients a new therapeutic alternative. The success of this technique will be confirmed by detecting postoperatively the presence of the transposed internal limiting membrane into the foveal region.

Conditions

Retinal Perforations

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ILMT

internal limiting membrane autologous transplantation (ILMT)

Group Type: EXPERIMENTAL

internal limiting membrane transplantation (ILMT)

Intervention Type: PROCEDURE

internal limiting membrane autologous transplantation (ILMT)

Interventions

internal limiting membrane transplantation (ILMT)

internal limiting membrane autologous transplantation (ILMT)

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Patient aged over 18,

2. Patient who already received at least a macular hole surgery,

3. Period of at least 4 months since last macular hole surgery,

4. Patient who underwent peeling of the internal limiting membrane,

5. Presents in OCT an open criteria macular hole,

6. The presence of a cataract in the preoperative clinical examination is not against indication. Its removal can be integrated to the surgery,

7. Patient who signed the consent form

Exclusion Criteria

1. Patient with against-indication or surgical anesthetic,

2. Macular Hole "flat open" or closed,

3. No progressive macular pathology other than the presence of a macular hole (retinal detachment, Macular degeneration related to age) Idiopathic and secondary macular holes are eligible if they have already been operated with the prior internal limiting membrane coat.

4. Patient unaffiliated or not the beneficiary of a social security system, or equivalent health insurance,

5. Pregnant or breastfeeding women,

6. Absence of patient consent,

7. Patient in exclusion period involved in another study,

8. Patient on administrative or judicial supervision

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Patrick LENOBLE, MD

Role: PRINCIPAL_INVESTIGATOR

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Locations

GHRMSA

Mulhouse, , France

Countries

France

Other Identifiers

2016-A01431-50

Identifier Type: REGISTRY

Identifier Source: secondary_id

GHRMSA 872

Identifier Type: -

Identifier Source: org_study_id